# Winrevair (sotatercept-csrk) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sotatercept-csrk

> The FDA approved Winrevair (sotatercept-csrk), sponsored by Merck & Co., Inc. (MRK), on March 26, 2024 for to treat pulmonary arterial hypertension.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Winrevair (sotatercept-csrk) FDA approved?

Yes. The FDA approved Winrevair (sotatercept-csrk), sponsored by Merck & Co., Inc. (MRK), on March 26, 2024 for to treat pulmonary arterial hypertension. FDA novel drug approvals: "Winrevair | sotatercept-csrk | 3/26/2024 | To treat pulmonary arterial hypertensionDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/sotatercept-csrk)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/sotatercept-csrk#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Winrevair (sotatercept-csrk) |
| Codes |  |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | To treat pulmonary arterial hypertension |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### March 26, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat pulmonary arterial hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Winrevair | sotatercept-csrk | 3/26/2024 | To treat pulmonary arterial hypertensionDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "BLA761363 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240326, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WINREVAIR (SOTATERCEPT-CSRK)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761363%22

### October 24, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761363 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20251024, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WINREVAIR (SOTATERCEPT-CSRK)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761363%22

### September 21, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761363 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260921, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WINREVAIR (SOTATERCEPT-CSRK)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761363%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sotatercept-csrk.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Winrevair (sotatercept-csrk) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sotatercept-csrk

```bibtex
@misc{secapidev_pdufa_sotatercept_csrk_20261116,
  title        = {Winrevair (sotatercept-csrk) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sotatercept-csrk}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sotatercept_csrk_20261116","title":"Winrevair (sotatercept-csrk) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sotatercept-csrk","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
